Ocugen (OCGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Nov, 2026Executive summary
Special meeting reconvened virtually on December 22, 2026, at 8:00 a.m. ET to vote on increasing authorized common shares by 250,000,000.
The board unanimously recommends voting FOR the share-authorization amendment.
Voting matters and shareholder proposals
Proposal 1 seeks a charter amendment adding 250,000,000 authorized common shares; this is the only proposal scheduled for a vote at the reconvened meeting.
Stockholders approved the adjournment proposal on September 21, 2026; the meeting was adjourned to October 5, then October 26, before being postponed to December 22.
Proxies submitted previously and not revoked will be voted as directed; if no direction was given, they will be voted FOR Proposal 1.
Proxy voting by phone or Internet closes at 11:59 p.m. ET on December 21, 2026; eligible holders may also vote online during the meeting.
Board of directors and corporate governance
The board unanimously supports Proposal 1; the proxy is solicited by the board, with Shankar Musunuri and Rita Johnson-Greene named as proxy appointees.
Latest events from Ocugen
- OCU400’s Q1 2027 readout anchors a broad, late-stage gene-therapy pipeline.OCGN
Stifel 2026 Healthcare Conference 2026 - Virtual special meeting set for Dec. 22; voting closes Dec. 21.OCGN
Proxy filing - 2027 pivotal readouts approach amid going-concern and share-conversion risks.OCGN
Q3 2026 - The 250 million-share authorization vote was deferred to October 26.OCGN
EGM 2026 - Share increase proposal lacked approval; meeting adjourned for further voting on October 5, 2026.OCGN
EGM 2026 - Late-stage gene therapies for major eye diseases advance toward BLA filings, with cash runway into 2028.OCGN
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote to increase authorized shares to support growth and commercialization.OCGN
Proxy filing - Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028.OCGN
Canaccord Genuity's 46th Annual Growth Conference - FDA cleared OCU410 phase III; $130M financing extends cash runway to 2028 amid going concern risk.OCGN
Q2 2026